689 related articles for article (PubMed ID: 30716176)
21. Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice.
Haga H; Yamada R; Izumi H; Shinoda Y; Kawahata I; Miyachi H; Fukunaga K
Pharmacol Biochem Behav; 2020 Apr; 191():172891. PubMed ID: 32126223
[TBL] [Abstract][Full Text] [Related]
22. Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice.
Finkelstein DI; Hare DJ; Billings JL; Sedjahtera A; Nurjono M; Arthofer E; George S; Culvenor JG; Bush AI; Adlard PA
ACS Chem Neurosci; 2016 Jan; 7(1):119-29. PubMed ID: 26481462
[TBL] [Abstract][Full Text] [Related]
23. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
[TBL] [Abstract][Full Text] [Related]
24. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
Paul R; Borah A
Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
[TBL] [Abstract][Full Text] [Related]
25. Impact of Dopamine Oxidation on Dopaminergic Neurodegeneration.
Zhang S; Wang R; Wang G
ACS Chem Neurosci; 2019 Feb; 10(2):945-953. PubMed ID: 30592597
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
27. Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.
Broderick PA; Wenning L; Li YS
J Neural Transm (Vienna); 2017 Jan; 124(1):57-78. PubMed ID: 27796511
[TBL] [Abstract][Full Text] [Related]
28. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
[TBL] [Abstract][Full Text] [Related]
29. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective effect of damaurone D in a C. elegans model of Parkinson's disease.
Lee SH; Han YT; Cha DS
Neurosci Lett; 2021 Mar; 747():135623. PubMed ID: 33482307
[TBL] [Abstract][Full Text] [Related]
31. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
[TBL] [Abstract][Full Text] [Related]
32. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
33. Biomimetic nanodecoys deliver cholesterol-modified heteroduplex oligonucleotide to target dopaminergic neurons for the treatment of Parkinson's disease.
Huang S; Li YJ; Wu JY; Hao XY; Xu WJ; Tang YC; Zhou M; Zhang JC; Luo S; Xiang DX
Acta Biomater; 2024 Mar; 177():316-331. PubMed ID: 38244661
[TBL] [Abstract][Full Text] [Related]
34. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.
De Deurwaerdère P; Di Giovanni G; Millan MJ
Prog Neurobiol; 2017 Apr; 151():57-100. PubMed ID: 27389773
[TBL] [Abstract][Full Text] [Related]
35. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
[TBL] [Abstract][Full Text] [Related]
36. Similar L-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation.
Li L; Sagot B; Zhou FM
Brain Res; 2015 Jul; 1615():12-21. PubMed ID: 25960345
[TBL] [Abstract][Full Text] [Related]
37. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
38. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
39. Modeling Parkinson's disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain.
Thakur P; Breger LS; Lundblad M; Wan OW; Mattsson B; Luk KC; Lee VMY; Trojanowski JQ; Björklund A
Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8284-E8293. PubMed ID: 28900002
[TBL] [Abstract][Full Text] [Related]
40. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.
Kingsbury AE; Marsden CD; Foster OJ
Mov Disord; 1999 Mar; 14(2):206-18. PubMed ID: 10091611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
